Last updated: May 27, 2026
Executive summary
- The global supply chain for fosnetupitant chloride/fosnetupitant chloride hydrochloride and palonosetron hydrochloride is dominated by (1) API producers of each active and (2) finished-dose and blend manufacturers that supply the combination product supply chain to branded and generic packagers.
- The most relevant supplier categories for sourcing are: API manufacturers for each hydrochloride, intermediate suppliers for salt forms, and CMOs/CDMOs for combination antiemetic drug product manufacturing.
- This answer is provided at the “supplier” level only where public, specific, company-level identification is available. If supplier names for these specific actives and salt forms are not present in the available source set, no company list is provided.
Who supplies fosnetupitant chloride hydrochloride API?
Answer: Supplier identification depends on whether the source lists a named manufacturer for fosnetupitant chloride hydrochloride (API) or only references generic “API sourcing.” Without company-level listings, suppliers cannot be stated.
What does “fosnetupitant chloride hydrochloride” sourcing typically include?
- Fosnetupitant (free base) to hydrochloride salt conversion via HCl treatment, followed by drying and controlled polymorph form management.
- Regulatory and quality documentation for the specific salt form used in finished-dose manufacture, including impurity profiling aligned with the approved specification.
Who supplies palonosetron hydrochloride API?
Answer: Supplier identification depends on whether a source provides named companies manufacturing palonosetron hydrochloride (API) rather than a general market description.
Common palonosetron hydrochloride supply model
- Manufacturers supply palonosetron hydrochloride API directly to branded manufacturers and to generic/combo product manufacturers that package under their own NDA/ANDA/label.
Do API suppliers overlap for fosnetupitant and palonosetron?
Answer: Overlap is uncommon at the API tier because the two actives are unrelated synthetic families, even if some CDMOs offer both drug substance procurement and drug product manufacturing.
Where overlap can occur
- CDMOs/CMOs that offer end-to-end antiemetic manufacturing can source both APIs from different upstream vendors, then formulate, blend, and package as a single combination.
Which companies supply the combination product workflow?
Answer: Combination product supply is typically handled by:
- Drug product manufacturers producing the finished dosage form (blend + tablet/capsule fill, packaging, and release).
- CMOs that manage manufacturing under quality agreements and provide release testing and stability commitments.
What to look for when mapping suppliers
- Company listings tied to approved drug product manufacturing sites.
- Supplier statements tied to specific drug substance (not just the combination) and specific salt forms.
What is the Orange Book status of fosnetupitant/palonosetron products and how does it affect sourcing?
Answer: Orange Book status can indicate which firms are launching generics and which patents block substitution. That in turn drives which suppliers and manufacturing networks are contracted for generic ready-to-supply capabilities.
Typical effect on supplier selection
- If there are active exclusivities and blocking patents, branded manufacturers tend to lock in supply via long-term sourcing.
- Generic entrants select API sources that can meet quality, impurity, and polymorph controls aligned with ANDA/FEED/CMC requirements.
What generic entry risks exist for fosnetupitant/palonosetron combinations?
Answer: Generic entry risks are driven by:
- Salt form control (hydrochloride form specs)
- Process validation and impurity limits for each API
- Combination formulation equivalence and dissolution performance
Supplier impact
- Suppliers must demonstrate reproducible synthesis and consistent impurity profiles.
- CDMOs must run the formulation under validated conditions that maintain bioequivalence.
What patent estate or litigation affects API/CDMO supplier qualification?
Answer: Litigation affects which firms can supply within US commercial timelines if:
- Patents protect the combination or specific formulation/method-of-use claims.
- Settlement agreements restrict certain generic launch timing.
Supplier qualification consequences
- When launch dates shift, upstream API purchasing schedules shift with them.
- Some suppliers build redundant capacity for salt form variants to support multiple customers.
Timeline: When do sourcing strategies typically change?
Answer: Sourcing strategy changes around:
- Regulatory approvals (NDA/ANDA status changes)
- Exclusivity and patent expiry windows
- Market entry by generics and authorized replacements
Practical supply-chain pacing
- API contracts often start 6 to 24 months before anticipated launches due to stability/CMC cycles.
Key Takeaways
- Supplier identification for fosnetupitant chloride hydrochloride and palonosetron hydrochloride must be backed by company-level public listings tied to those exact actives and salt forms.
- In most cases, the sourcing landscape separates into API manufacturers for each active and CMOs/CDMOs that execute combination drug product manufacturing after procurement.
- Patent and regulatory status influences supplier contracting intensity and which firms can support generic or authorized entry timing.
FAQs
- Who typically manufactures palonosetron hydrochloride API for antiemetic combination products in the US?
- Which factors determine API polymorph and impurity acceptance for hydrochloride salt forms of fosnetupitant?
- How do CDMOs structure contracts to supply both fosnetupitant and palonosetron to a single finished-dose manufacturer?
- What CMC package elements are most scrutinized for ANDA approval of combination antiemetic products?
- How do settlement agreements tied to Paragraph IV litigation affect upstream API sourcing schedules?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. (accessed 2026-05-28).
- FDA. Approved Drug Products and Biological Products with Therapeutic Equivalence Evaluations (Drug Databases). US Food and Drug Administration. (accessed 2026-05-28).
